RenovoRx Inc (RNXT) FinancialsRNXTRenovoRx Inc

Evaluating the bottom line, RenovoRx Inc maintains a gross margin of 84.27%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -368.43%, while the net margin is -320.24%. These profitability ratios, combined with a Return on Equity (ROE) of -125.23%, provide a clear picture of how effectively RNXT converts its operational activities into shareholder value.

In the context of the broader market, RNXT competes directly with industry leaders such as SKIN and ECOR. With a market capitalization of $53.70M, it holds a significant position in the sector. When comparing efficiency, RNXT's gross margin of 84.27% stands against SKIN's 68.42% and ECOR's 88.47%. Such benchmarking helps identify whether RenovoRx Inc is trading at a premium or discount relative to its financial performance.

RenovoRx has shown significant revenue growth, with Q2 2026 revenue reaching $909,000, marking a 61% increase from the previous quarter. Gross margins are also strong, reported at 84% for Q2 2026, indicating efficient operations despite ongoing net losses.